Biotech firm REGENXBIO files for a $100 million share sale following a 1.7% post-market decline in its stock.
REGENXBIO announced plans to raise $100 million through a public offering of its common stock. The move follows a 1.7% drop in its shares during post-market trading on Thursday.
The company intends to use underwriters for the offering, which includes granting them an option to purchase additional shares. REGENXBIO has not disclosed the specific use of proceeds or pricing details.
Shares of RGNX had previously closed lower ahead of the announcement, reflecting investor reaction to the capital raise plans.